SI3099687T1 - Macrocycles with hetrocyclic p2' groups as factor xia inhibitors - Google Patents

Macrocycles with hetrocyclic p2' groups as factor xia inhibitors Download PDF

Info

Publication number
SI3099687T1
SI3099687T1 SI201530317T SI201530317T SI3099687T1 SI 3099687 T1 SI3099687 T1 SI 3099687T1 SI 201530317 T SI201530317 T SI 201530317T SI 201530317 T SI201530317 T SI 201530317T SI 3099687 T1 SI3099687 T1 SI 3099687T1
Authority
SI
Slovenia
Prior art keywords
independently selected
alkyl
optionally substituted
cycloalkyl
heterocyclyl
Prior art date
Application number
SI201530317T
Other languages
English (en)
Slovenian (sl)
Inventor
James R. Corte
Lucca Indawati De
Tianan Fang
Wu Yang
Yufeng Wang
Andrew K. Dilger
Kumar Balashanmuga Pabbisetty
William R. Ewing
Yeheng Zhu
Ruth R. Wexler
Donald J. P. Pinto
Michael J. Orwat
Leon M. Ii Smith
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484570&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3099687(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SI3099687T1 publication Critical patent/SI3099687T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compression Or Coding Systems Of Tv Signals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
SI201530317T 2014-01-31 2015-01-30 Macrocycles with hetrocyclic p2' groups as factor xia inhibitors SI3099687T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461933942P 2014-01-31 2014-01-31
US201462058293P 2014-10-01 2014-10-01
EP15705860.3A EP3099687B1 (en) 2014-01-31 2015-01-30 Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
PCT/US2015/013654 WO2015116886A1 (en) 2014-01-31 2015-01-30 Macrocycles with hetrocyclic p2' groups as factor xia inhibitors

Publications (1)

Publication Number Publication Date
SI3099687T1 true SI3099687T1 (en) 2018-08-31

Family

ID=52484570

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201530317T SI3099687T1 (en) 2014-01-31 2015-01-30 Macrocycles with hetrocyclic p2' groups as factor xia inhibitors

Country Status (32)

Country Link
US (2) US9777001B2 (https=)
EP (4) EP3099686B1 (https=)
JP (7) JP6464176B2 (https=)
KR (3) KR20240017118A (https=)
CN (4) CN116987080A (https=)
AU (5) AU2015210904C1 (https=)
BR (1) BR112016015717B1 (https=)
CA (1) CA2937739C (https=)
CL (1) CL2016001933A1 (https=)
CY (1) CY1120702T1 (https=)
DK (1) DK3099687T3 (https=)
EA (1) EA030222B1 (https=)
ES (3) ES2687498T3 (https=)
HR (1) HRP20181339T1 (https=)
HU (1) HUE040226T2 (https=)
IL (5) IL298983B2 (https=)
LT (1) LT3099687T (https=)
MX (2) MX377545B (https=)
MY (1) MY190429A (https=)
NZ (2) NZ723762A (https=)
PE (2) PE20161069A1 (https=)
PH (2) PH12016501249B1 (https=)
PL (1) PL3099687T3 (https=)
PT (1) PT3099687T (https=)
RS (1) RS57659B1 (https=)
SG (2) SG10201908467RA (https=)
SI (1) SI3099687T1 (https=)
SM (1) SMT201800505T1 (https=)
TW (4) TW201613922A (https=)
UY (3) UY40230A (https=)
WO (2) WO2015116885A1 (https=)
ZA (1) ZA201606011B (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
KR101937514B1 (ko) 2011-10-14 2019-01-10 브리스톨-마이어스 스큅 컴퍼니 인자 xia 억제제로서의 치환된 테트라히드로이소퀴놀린 화합물
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
CN116987080A (zh) * 2014-01-31 2023-11-03 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
NO2760821T3 (https=) 2014-01-31 2018-03-10
EP2913330A1 (en) 2014-02-27 2015-09-02 Laboratoire Biodim Condensed derivatives of imidazole useful as pharmaceuticals
CN107074821B (zh) 2014-09-04 2020-05-22 百时美施贵宝公司 为fxia抑制剂的二酰胺大环化合物
NO2721243T3 (https=) * 2014-10-01 2018-10-20
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JP6662865B2 (ja) 2014-10-01 2020-03-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ボロン酸誘導体
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
WO2016205482A1 (en) 2015-06-19 2016-12-22 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
ES2871111T3 (es) 2015-07-29 2021-10-28 Bristol Myers Squibb Co Inhibidores macrocíclicos del factor XIa que contienen un grupo P2' no aromático
US10287288B2 (en) 2015-07-29 2019-05-14 Bristol-Myers Squibb Factor XIa macrocyclic inhibitors bearing alkyl or cycloalkyl P2' moieties
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
WO2017074833A1 (en) 2015-10-29 2017-05-04 Merck Sharp & Dohme Corp. Macrocyclic spirocarbamate derivatives as factor xia inhibitors, pharmaceutically acceptable compositions and their use
MX387515B (es) * 2015-10-29 2025-03-18 Merck Sharp & Dohme Llc Inhibidores de factor xia.
KR20180117156A (ko) 2016-03-02 2018-10-26 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제 활성을 갖는 디아미드 마크로사이클
HRP20210847T1 (hr) 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. Supstituirani derivati indola kao inhibitori replikacije denga virusa
MX2018011788A (es) 2016-03-31 2019-05-20 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR102359766B1 (ko) 2016-04-01 2022-02-07 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서 치환된 인돌 화합물 유도체
AR109304A1 (es) 2016-08-10 2018-11-21 Sumitomo Chemical Co Compuesto de oxadiazol y su uso
EP3500556B1 (en) 2016-08-22 2023-08-02 Merck Sharp & Dohme LLC Pyridine-1-oxide derivatives and their use as factor xia inhibitors
WO2018133793A1 (zh) * 2017-01-18 2018-07-26 广东东阳光药业有限公司 凝血因子XIa抑制剂及其用途
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EA201992782A1 (ru) 2017-05-22 2020-03-24 Янссен Фармасьютикалз, Инк. Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
CN110753682B (zh) 2017-05-22 2023-06-30 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚啉衍生物
WO2019011166A1 (zh) * 2017-07-14 2019-01-17 四川科伦博泰生物医药股份有限公司 大环酰胺化合物及其药物组合物和用途
BR112021020368A2 (pt) 2019-04-11 2021-12-07 Bristol Myers Squibb Co Opções sintéticas para a fabricação de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexa-hidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona
TW202104228A (zh) * 2019-04-11 2021-02-01 美商必治妥美雅史谷比公司 用於達到治療血漿濃度之增加效能的非晶形固體及經溶解調配物
WO2020211781A1 (zh) * 2019-04-16 2020-10-22 南京明德新药研发有限公司 作为XIa因子抑制剂的大环衍生物
JP7286001B2 (ja) 2019-07-23 2023-06-02 メッドシャイン ディスカバリー インコーポレイテッド 第ＸＩａ因子阻害剤としての大環状誘導体
TWI749881B (zh) * 2019-11-21 2021-12-11 大陸商深圳信立泰藥業股份有限公司 二氧代哌類衍生物、其製備方法及其在醫藥上的應用
JP2023521411A (ja) * 2020-04-10 2023-05-24 ブリストル－マイヤーズ スクイブ カンパニー （９ｒ，１３ｓ）－１３－｛４－［５－クロロ－２－（４－クロロ－１ｈ－１，２，３－トリアゾール－１－イル）フェニル］－６－オキソ－１，６－ジヒドロピリミジン－１－イル｝－３－（ジフルオロメチル）－９－メチル－３，４，７，１５－テトラアザトリシクロ［１２．３．１．０２，６］オクタデカ－１（１８），２（６），４，１４，１６－ペンタエン－８－オンの結晶体
TW202229280A (zh) * 2020-10-12 2022-08-01 美商必治妥美雅史谷比公司 （６ｒ，１０ｓ）－１０－｛４－［５－氯－２－（４－氯－１ｈ－１，２，３－三唑－１－基）苯基］－６－側氧基－１（６ｈ）－嘧啶基｝－１－（二氟甲基）－６－甲基－１，４，７，８，９，１０－六氫－１１，１５－（亞甲橋基）吡唑并［４，３－ｂ］［１，７］二氮雜環十四炔－５（６ｈ）－酮之製備方法
JP7517964B2 (ja) * 2020-11-27 2024-07-17 シャープ株式会社 電子機器、電子機器の制御方法、プログラム、記録媒体
CN112608274B (zh) * 2020-12-30 2022-09-06 西南大学 一种手性胺化合物的催化合成方法及其化合物
CA3204552A1 (en) * 2021-01-08 2022-07-14 Joseph M. LUETTGEN Antibodies and antigen binding peptides for factor xia inhibitors and uses thereof
CN112876461B (zh) * 2021-01-20 2022-12-30 上海零诺生物科技有限公司 尼古丁及其中间体的制备方法
CN117603208A (zh) * 2021-04-21 2024-02-27 上海美悦生物科技发展有限公司 FXIa抑制剂及其药物组合物、制备方法和用途
EP4472624A4 (en) * 2022-02-03 2026-01-07 De Shaw Res Llc PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS
PE20251672A1 (es) * 2022-06-08 2025-06-30 Blossomhill Therapeutics Inc Macrociclos de indazol y su uso
KR20260032556A (ko) * 2023-06-30 2026-03-09 심천 사루브리스 퍼머수티칼스 컴퍼니 리미티드 다치환된 거대환식 화합물 및 이의 제조 방법과 용도
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1525186A (fr) 1967-03-29 1968-05-17 Roussel Uclaf Nouvelles pénicillines et procédé de préparation
DE3065190D1 (en) 1979-11-05 1983-11-10 Beecham Group Plc Enzyme derivatives, and their preparation
DE4034829A1 (de) 1990-11-02 1992-05-07 Merck Patent Gmbh Cyclopeptide
JP3190431B2 (ja) 1991-07-01 2001-07-23 三菱化学株式会社 ケトン誘導体
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
WO1996034010A2 (en) 1995-03-29 1996-10-31 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5624936A (en) 1995-03-29 1997-04-29 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU717298B2 (en) 1996-04-03 2000-03-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5869682A (en) 1996-04-03 1999-02-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
ZA985247B (en) 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
DK1064298T3 (da) 1998-03-19 2009-01-19 Vertex Pharma Inhibitorer af caspaser
AU763839B2 (en) 1998-05-26 2003-07-31 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
KR20010101355A (ko) 1999-01-02 2001-11-14 로버트 흐라이탁, 미쉘 베스트 신규한 말론산 유도체, 이의 제조 방법, 이의 용도 및이를 함유하는 약제학적 조성물(인자 ｘａ 활성 억제)
EP1016663A1 (en) 1999-01-02 2000-07-05 Aventis Pharma Deutschland GmbH Novel malonic acid derivatives, processes for their preparation, their use and pharmaceutical compositions containing them (inhibition of factor Xa activity)
CZ20013577A3 (cs) 1999-04-09 2002-07-17 Basf Aktiengesellschaft Inhibitory komplementních proteáz s nízkou molekulovou hmotností
EP1192135A2 (en) 1999-06-14 2002-04-03 Eli Lilly And Company Serine protease inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
EP1125925A1 (en) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Amine derivatives for the treatment of apoptosis
DE60115227T2 (de) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
WO2003011222A2 (en) * 2001-07-27 2003-02-13 Merck & Co., Inc. Thrombin inhibitors
US6951840B2 (en) 2001-08-31 2005-10-04 Eli Lilly And Company Lipoglycopeptide antibiotics
CA2461202C (en) 2001-09-21 2011-07-12 Donald Pinto Lactam-containing compounds and derivatives thereof as factor xa inhibitors
AU2002357692A1 (en) 2001-11-09 2003-05-26 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
WO2003106438A1 (en) 2002-06-18 2003-12-24 The Scripps Research Institute Synthesis of diazonamide "a" core
US20040180855A1 (en) 2003-02-19 2004-09-16 Schumacher William A. Methods of treating thrombosis with reduced risk of increased bleeding times
US7138412B2 (en) 2003-03-11 2006-11-21 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives useful as serine protease inhibitors
US7129264B2 (en) 2003-04-16 2006-10-31 Bristol-Myers Squibb Company Biarylmethyl indolines and indoles as antithromboembolic agents
WO2005014533A2 (en) 2003-08-08 2005-02-17 Transtech Pharma, Inc. Aryl and heteroaryl compounds, compositions, and methods of use
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP1773348A4 (en) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
WO2006076575A2 (en) 2005-01-13 2006-07-20 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
WO2006089005A2 (en) 2005-02-17 2006-08-24 Bristol-Myers Squibb Company Combination of selective factor viia and/or xia and plasma kallikrein inhibitors
US20070111947A1 (en) 2005-10-14 2007-05-17 Mcmurry Thomas J Fibrin targeted therapeutics
CA2627426A1 (en) 2005-11-11 2007-05-18 Markus Boehringer Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa
EP1981854B1 (en) 2005-12-14 2011-06-01 Bristol-Myers Squibb Company Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor xia inhibitors
AU2006325746A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
WO2007070816A2 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Thiophene derivatives as factor xia inhibitors
CN101389613B (zh) * 2005-12-23 2011-10-12 布里斯托尔-迈尔斯.斯奎布公司 用作抗凝血药的大环凝血因子viia抑制剂
AR058380A1 (es) 2005-12-23 2008-01-30 Bristol Myers Squibb Co Inhibidores del factor viia macrociclicos utiles como anticoagulantes
CN101605779B (zh) 2006-12-15 2013-11-20 百时美施贵宝公司 作为凝血因子xia抑制剂的芳基丙酰胺、芳基丙烯酰胺、芳基丙炔酰胺或芳基甲基脲类似物
PE20081775A1 (es) 2006-12-20 2008-12-18 Bristol Myers Squibb Co Compuestos macrociclicos como inhibidores del factor viia
AR067329A1 (es) 2007-06-13 2009-10-07 Bristol Myers Squibb Co Analogos dipeptidos como inhibidores del factor de coagulacion
US8324199B2 (en) 2008-03-13 2012-12-04 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
US8624040B2 (en) 2009-06-22 2014-01-07 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011002520A2 (en) 2009-07-02 2011-01-06 Angion Biomedica Corp. Small molecule inhibitors of parp activity
WO2011017296A1 (en) 2009-08-04 2011-02-10 Schering Corporation 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors
CN102596933B (zh) * 2009-09-09 2014-09-17 杜邦公司 除草剂嘧啶酮衍生物
ES2674745T3 (es) * 2010-02-11 2018-07-03 Bristol-Myers Squibb Company Macrociclos como inhibidores del factor XIa
WO2013009527A2 (en) 2011-07-08 2013-01-17 Merck Sharp & Dohme Corp. Factor ixa inhibitors
TW201311689A (zh) 2011-08-05 2013-03-16 必治妥美雅史谷比公司 作為因子ｘｉａ抑制劑之新穎巨環化合物
TW201319068A (zh) * 2011-08-05 2013-05-16 必治妥美雅史谷比公司 作為ｘｉａ因子抑制劑之環狀ｐ１接合劑
KR101937514B1 (ko) 2011-10-14 2019-01-10 브리스톨-마이어스 스큅 컴퍼니 인자 xia 억제제로서의 치환된 테트라히드로이소퀴놀린 화합물
ES2579832T3 (es) 2011-10-14 2016-08-17 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa
EP2766345B1 (en) 2011-10-14 2016-03-16 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
RU2630677C2 (ru) * 2011-12-21 2017-09-12 Оно Фармасьютикал Ко., Лтд. Соединения
GB2497806A (en) 2011-12-21 2013-06-26 Ono Pharmaceutical Co Pyridinone and pyrimidinone derivatives as factor XIa inhibitors
US20140378474A1 (en) 2012-01-27 2014-12-25 Novartis Ag 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors
EP2807156A1 (en) 2012-01-27 2014-12-03 Novartis AG Aminopyridine derivatives as plasma kallikrein inhibitors
JP2015083542A (ja) 2012-02-08 2015-04-30 大日本住友製薬株式会社 ３位置換プロリン誘導体
EP2847228B1 (en) 2012-05-10 2018-07-25 Bayer Pharma Aktiengesellschaft Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof
GB201209138D0 (en) 2012-05-24 2012-07-04 Ono Pharmaceutical Co Compounds
US9758480B2 (en) 2012-07-19 2017-09-12 Sumitomo Dainippon Pharma Co., Ltd. 1-(cycloalkyl-carbonyl)proline derivative
MX361759B (es) * 2012-08-03 2018-12-17 Bristol Myers Squibb Co Compuestos macrocíclicos de dihidropiridona como inhibidores del factor xia y el uso de los mismos en el tratamiento de un trastorno tromboembólico.
KR20150038369A (ko) * 2012-08-03 2015-04-08 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 디히드로피리돈 P1
TR201807316T4 (tr) 2012-10-12 2018-06-21 Bristol Myers Squibb Co Bir faktör XIa inhibitörünün kristalli formları.
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2906552B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9708308B2 (en) 2012-12-19 2017-07-18 Merck Sharp Dohme Corp. Factor IXa inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
ES2712699T3 (es) 2013-03-25 2019-05-14 Bristol Myers Squibb Co Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
CA2918814C (en) 2013-07-23 2021-10-12 Bayer Pharma Aktiengesellschaft Substituted oxopyridine derivatives and use thereof as factor xia/plasma
UY35745A (es) 2013-09-26 2015-04-30 Bayer Pharma AG Derivados sustituidos de fenilalanina
TN2016000107A1 (en) 2013-09-26 2017-07-05 Bayer Pharma AG Substituted phenylalanine derivatives
EP3049403A1 (de) 2013-09-26 2016-08-03 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate
US20160237045A1 (en) 2013-09-26 2016-08-18 Bayer Pharma Aktiengesellschaft Substituted phenylalanine derivatives
EP3049408A1 (de) 2013-09-26 2016-08-03 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate
EP3049407A1 (de) 2013-09-26 2016-08-03 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate als faktor xia modulatoren
US20160244437A1 (en) 2013-09-26 2016-08-25 Bayer Pharma Aktiengesellschaft Substituted phenylalanine derivatives
WO2015044170A1 (de) 2013-09-26 2015-04-02 Bayer Pharma Aktiengesellschaft Substituierte phenylalanin-derivate und ihre verwendung zur behandlung von thrombotischen / thromboembolischen erkrankungen
WO2015047973A1 (en) 2013-09-27 2015-04-02 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
WO2015054087A1 (en) 2013-10-07 2015-04-16 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
JP6337750B2 (ja) 2013-11-22 2018-06-06 小野薬品工業株式会社 化合物
KR20160107322A (ko) 2014-01-14 2016-09-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 축합 ５－옥사졸리디논 유도체
CN116987080A (zh) * 2014-01-31 2023-11-03 百时美施贵宝公司 作为因子xia抑制剂的具有杂环p2′基团的大环化合物
NO2760821T3 (https=) 2014-01-31 2018-03-10
RU2733405C2 (ru) 2014-02-07 2020-10-01 Экзитера Фармасьютикалз Инк. Терапевтические соединения и композиции
WO2015123090A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Factor xia inhibitors
US9676723B2 (en) 2014-02-11 2017-06-13 Merck Sharp & Dohme Corp Factor XIa inhibitors
EP3104703B1 (en) 2014-02-11 2020-11-18 Merck Sharp & Dohme Corp. Factor xia inhibitors
CN105829298B (zh) 2014-02-14 2019-02-01 四川海思科制药有限公司 一种吡啶酮或嘧啶酮衍生物、及其制备方法和应用
CN106257976B (zh) 2014-03-07 2021-02-02 拜奥克里斯特制药公司 人类血浆激肽释放酶抑制剂
WO2015160636A1 (en) 2014-04-16 2015-10-22 Merck Sharp & Dohme Corp. Factor ixa inhibitors
EP3131896B1 (en) 2014-04-16 2019-01-30 Merck Sharp & Dohme Corp. Factor ixa inhibitors
GB201409202D0 (en) * 2014-05-23 2014-07-09 Ffei Ltd Improvements in imaging microscope samples
KR20150136294A (ko) 2014-05-27 2015-12-07 주식회사 레고켐 바이오사이언스 인자 ＸＩａ 억제 활성을 가지는 신규한 화합물
JP2017517512A (ja) 2014-05-28 2017-06-29 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 第ｘｉａ因子インヒビター
US10138236B2 (en) 2014-09-24 2018-11-27 Bayer Pharma Aktiengesellschaft Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
NO2721243T3 (https=) 2014-10-01 2018-10-20
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
MX385021B (es) 2014-12-10 2025-03-14 Ono Pharmaceutical Co Derivado de dihidroindolizinona.
WO2016205482A1 (en) 2015-06-19 2016-12-22 Bristol-Myers Squibb Company Diamide macrocycles as factor xia inhibitors

Also Published As

Publication number Publication date
MX377545B (es) 2025-03-10
MX2016009230A (es) 2016-10-03
JP2019077704A (ja) 2019-05-23
AU2015210904C1 (en) 2019-08-29
HUE040226T2 (hu) 2019-02-28
ES2893251T3 (es) 2022-02-08
TWI859674B (zh) 2024-10-21
JP2019094354A (ja) 2019-06-20
ZA201606011B (en) 2018-05-30
JP6505727B2 (ja) 2019-04-24
UY35975A (es) 2015-07-31
LT3099687T (lt) 2018-09-10
NZ761182A (en) 2023-04-28
PE20210470A1 (es) 2021-03-08
TWI790421B (zh) 2023-01-21
JP2017504642A (ja) 2017-02-09
PH12016501249A1 (en) 2016-08-15
IL272377B2 (en) 2023-05-01
JP6630004B2 (ja) 2020-01-15
TW201615639A (zh) 2016-05-01
AU2023203695A1 (en) 2023-07-06
RS57659B1 (sr) 2018-11-30
NZ723762A (en) 2023-03-31
CL2016001933A1 (es) 2017-03-24
SMT201800505T1 (it) 2018-11-09
WO2015116885A1 (en) 2015-08-06
CN106132962B (zh) 2018-09-07
TW202340188A (zh) 2023-10-16
JP6464176B2 (ja) 2019-02-06
JP2025185049A (ja) 2025-12-18
IL298983A (en) 2023-02-01
CY1120702T1 (el) 2019-12-11
CN106132962A (zh) 2016-11-16
IL272377B1 (en) 2023-01-01
MY190429A (en) 2022-04-21
EP3099686A1 (en) 2016-12-07
CN105980384B (zh) 2019-11-15
DK3099687T3 (en) 2018-10-22
CA2937739C (en) 2024-04-16
CN110845498A (zh) 2020-02-28
KR102631769B1 (ko) 2024-02-01
UY35971A (es) 2015-07-31
CN110845498B (zh) 2023-02-17
JP7325464B2 (ja) 2023-08-14
US20170002006A1 (en) 2017-01-05
IL246964A0 (en) 2016-09-29
TWI688564B (zh) 2020-03-21
EP3099687A1 (en) 2016-12-07
KR20160113267A (ko) 2016-09-28
IL246964B (en) 2020-02-27
PE20161069A1 (es) 2016-10-22
EP3099686B1 (en) 2020-03-11
MX2020012520A (es) 2021-02-16
KR102413453B1 (ko) 2022-06-28
UY40230A (es) 2023-08-15
AU2015210904B2 (en) 2019-05-16
IL298983B2 (en) 2024-03-01
IL298983B1 (en) 2023-11-01
IL307212A (en) 2023-11-01
IL322255A (en) 2025-09-01
KR20240017118A (ko) 2024-02-06
AU2015210904A1 (en) 2016-09-15
JP6854067B2 (ja) 2021-04-07
BR112016015717B1 (pt) 2023-04-04
AU2019216617B2 (en) 2021-03-18
ES2687498T3 (es) 2018-10-25
PH12021550418A1 (en) 2021-11-15
TW202037595A (zh) 2020-10-16
US9777001B2 (en) 2017-10-03
HRP20181339T1 (hr) 2018-12-28
EP3392249B1 (en) 2021-08-25
BR112016015717A8 (pt) 2018-05-02
JP2017504641A (ja) 2017-02-09
WO2015116886A1 (en) 2015-08-06
AU2019216617A1 (en) 2019-09-05
SG11201606209PA (en) 2016-08-30
JP2023133468A (ja) 2023-09-22
IL272377A (en) 2020-03-31
EA201691471A1 (ru) 2016-12-30
CA2937739A1 (en) 2015-08-06
AU2025201886A1 (en) 2025-04-03
US20170096429A1 (en) 2017-04-06
BR112016015717A2 (pt) 2017-08-08
PH12016501249B1 (en) 2022-01-21
EP3988549A1 (en) 2022-04-27
CN116987080A (zh) 2023-11-03
PT3099687T (pt) 2018-10-19
PL3099687T3 (pl) 2018-12-31
TW201613922A (en) 2016-04-16
AU2021203968B2 (en) 2023-03-30
JP2021088610A (ja) 2021-06-10
AU2021203968A1 (en) 2021-07-08
EP3099687B1 (en) 2018-07-04
EP3392249A1 (en) 2018-10-24
ES2784841T3 (es) 2020-10-01
KR20220093390A (ko) 2022-07-05
EA030222B1 (ru) 2018-07-31
SG10201908467RA (en) 2019-10-30
CN105980384A (zh) 2016-09-28

Similar Documents

Publication Publication Date Title
SI3099687T1 (en) Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2016517417A5 (https=)
RU2019100164A (ru) Гетероциклическое соединение, используемое как ингибитор fgfr
RU2014141579A (ru) Гетероциклические соединения в качестве ингибиторов бета-лактамаз
AR046792A1 (es) Fenilalanina-amidas sustituidas por heteroaroilo, un procedimiento para su preparacion, utilizacion de las mismas como herbicidas y productos fitosa-nitarios que los contienen como principio activo
RU2014114466A (ru) ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/β-КАТЕНИНА
HRP20170104T1 (hr) Derivati tipa azaindazola ili diazaindazola za liječenje boli
RU2010126105A (ru) Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства
AR048346A1 (es) Piridonas sustituidas como inhibidores de poli(adp-ribosa)-polimerasa (parp), composiciones farmaceuticas que las contienen y el uso de las mismas para el tratamiento de trastornos cardiovasculares y del sistema nervioso central.
EA202090658A1 (ru) Ингибиторы кэп-зависимой эндонуклеазы
RU2017138972A (ru) Ингибиторы репликации вируса иммунодефицита человека
JP2019518766A5 (https=)
ME02583B (me) Jedinjenja pirolidinil uree, pirolidinil tiouree i pirolidinil guanidina kao inhibitori trka kinaze
RU2008110949A (ru) Соединения и композиции-иммуносупрессанты
RU2015102834A (ru) Фунгицидные гетероциклические карбоксамиды
SI3022192T1 (en) Piperidinyl indole derivatives and their use as inhibitors of complementary factor B
JP2018537483A5 (https=)
JP2017507160A5 (https=)
JP2018535963A5 (https=)
HRP20151370T1 (hr) Derivati benzotiazola kao sredstva protiv raka
JP2014523432A5 (https=)
BRPI0418127A (pt) uso de um composto, seus sais, e derivados farmaceuticamente aceitáveis dos mesmos, método para o tratamento de infecções envolvendo vìrus da sub-famìlia pneumovirinae, formulação farmacêutica, métodos para tratar mamìferos infectados e para prevenir a infecção de mamìferos com vìrus da sub-famìlia pneumovirinae, composto, seus sais, e derivados farmaceuticamente aceitáveis dos mesmos, composto e a forma n-óxido e sal piridìnio do mesmo, e, método de separação de enantiÈmeros de um composto
RU2012144317A (ru) Противоинфекционные соединения
RU2011103454A (ru) Бициклические гетероциклы в качестве ингибиторов киназы мек